Target-mediated drug disposition
Target-mediated drug disposition (TMDD) is a term used in pharmacokinetics to describe the phenomenon where the pharmacokinetics of a drug are significantly affected by its own pharmacodynamics. This typically occurs when a drug has a high affinity for a specific target such as a receptor, enzyme, or transporter, and the drug-target interaction significantly influences the drug's distribution and elimination.
Overview[edit | edit source]
TMDD is often observed with biologic drugs, including monoclonal antibodies, recombinant proteins, and gene therapies. These drugs often have high affinities for their targets, and the targets can be present in limited quantities. As a result, the drug-target interaction can significantly influence the drug's pharmacokinetics.
Mechanism[edit | edit source]
The mechanism of TMDD involves the binding of the drug to its target. This binding can lead to the internalization and degradation of the drug-target complex, effectively removing the drug from circulation. This can result in nonlinear pharmacokinetics, where the drug's clearance rate changes with its concentration.
In some cases, the target can be upregulated in response to drug binding, leading to an increase in the drug's clearance rate. This is known as target-mediated drug induction.
Mathematical modeling[edit | edit source]
Mathematical models have been developed to describe and predict the pharmacokinetics of drugs exhibiting TMDD. These models typically involve differential equations that describe the rates of drug absorption, distribution, metabolism, and excretion, as well as the rates of target binding and internalization.
Clinical implications[edit | edit source]
Understanding TMDD is important for the development and dosing of new drugs. If a drug exhibits TMDD, its dose-response relationship may be nonlinear, and its optimal dose may depend on the patient's target levels. Additionally, TMDD can lead to variability in drug response between patients, which can complicate drug development and dosing strategies.
See also[edit | edit source]
- Pharmacokinetics
- Pharmacodynamics
- Biologic drugs
- Monoclonal antibodies
- Recombinant proteins
- Gene therapies
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
